Investor Relations

Company Overview

RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via our proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. Our lead product candidate, RenovoGem, is a combination of gemcitabine and our patented delivery system regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC).

Targeted therapy via RenovoTAMP platform safely and without transmission to non-targeted areas, is our primary focus. RenovoRx’s patent portfolio currently includes seven issued US patents and one European patent for ourtechnology with several additional patents pending in the US, Europe, and Asia.

Latest Financial Results

Q2 2022

Quarter Ended June 30, 2022

Latest Annual Filing

For Fiscal Year Ending December 31, 2021

Stock Snapshot

IR Contacts

Company

RenovoRX, Inc.
4546 El Camino Real
Suite B1
Los Altos, CA 94022
info@renovorx.com

Investor Relations

KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254
renovorx@kcsa.com

Transfer Agent

Pacific Stock Transfer Company
6725 Via Austi Pkwy
Suite 300
Las Vegas, Nevada 89119
T: 702-361-3033
F: 702-433-1979

Menu

Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.